Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry-Reference-Cited by-同舟云学术

Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry

Published:2021-10-19 Issue: Volume: Page:
ISSN:1478-2189
Container-title:Musculoskeletal Care
language:en
Short-container-title:Musculoskeletal Care

Author:

Pombo‐Suárez Manuel¹,Sanchez‐Piedra Carlos²,Ruiz‐Montesino Dolores³,Diaz‐Torne Cesar⁴,Jovaní Vega⁵,Cea‐Calvo Luis⁶,Castrejón Isabel⁷⁸

Affiliation:

1. Servicio de Reumatología Hospital Universitario de Santiago de Compostela Santiago de Compostela Spain

2. Unidad de investigación, Sociedad Española de Reumatología Madrid Spain

3. Servicio de Reumatología Hospital Universitario Virgen de la Macarena Sevilla Spain

4. Servicio de Reumatología Hospital Universitario Santa Creu i Sant Pau Barcelona Spain

5. Servicio de Reumatología Hospital General Universitario de Alicante Alicante Spain

6. Medical Affairs MSD España Madrid Spain

7. Servicio de Reumatología Hospital General Universitario Gregorio Marañón Madrid Spain

8. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM) Madrid Spain

Publisher

Wiley

Subject

Nursing (miscellaneous),Rehabilitation,Physical Therapy, Sports Therapy and Rehabilitation,Orthopedics and Sports Medicine,Chiropractics,Rheumatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/msc.1595

Reference15 articles.

1. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence

2. Patient and Physician Expectations of Add-On Treatment With Golimumab for Rheumatoid Arthritis: Relationships Between Expectations and Clinical and Quality of Life Outcomes

3. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

4. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry

5. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases;Advances in Rheumatology;2023-06-07